Will Lenskart IPO Break the Trend Set by Other Shark Tank India Founders?
About Shark Tank Founders’ IPO Performance
The Indian startup ecosystem has witnessed several Shark Tank India judges steering their ventures into the public market. While the excitement around their IPOs was immense, post-listing performance has been mixed — highlighting the difference between brand popularity and long-term shareholder value creation.
IPO Snapshot – Shark Tank India Judges’ Companies
| Founder | Company | IPO Listing Price | Current Price | Change | Tenure Since Listing |
|---|---|---|---|---|---|
| Ghazal Alagh | Honasa (Mamaearth) | ₹330 | ₹271 | -18% | 3 Years |
| Namita Thapar | Emcure Pharma | ₹1,325 | ₹1,326 | 0% | 15 Months |
| Peyush Bansal | Lenskart | — | — | IPO Expected | — |
Mamaearth (Honasa) continues to struggle below its listing price despite aggressive marketing and product diversification, showing that sentiment cannot sustain without consistent earnings growth.
Emcure Pharma has delivered flat returns since listing, reflecting stable but unexciting performance typical of the pharmaceutical sector during consolidation phases.
As Lenskart prepares for its IPO, investors are keenly watching whether Peyush Bansal can reverse the underwhelming trend seen with his Shark Tank peers.
Follow short-term momentum through Nifty Tip and BankNifty Tips
Key Takeaways from Previous IPOs
- ✅ Strong brand recall helped generate high initial demand during IPOs.
- ⚙️ However, post-listing price corrections show valuations were stretched at debut.
- 📉 Consumer startups with limited profitability struggle to sustain premium multiples.
- 💡 Institutional investors are now more cautious, focusing on companies with clear earnings visibility.
Can Lenskart Change the Narrative?
- 💡 Backed by steady growth and omni-channel presence, Lenskart has stronger fundamentals than previous Shark Tank listings.
- 💡 Global expansion in the Middle East and Southeast Asia offers upside potential.
- ⚠️ High valuation and competitive retail optics market remain near-term risks.
- ⚙️ Analysts expect healthy subscription driven by institutional and HNI demand.
With the eyewear major backed by marquee investors such as Temasek, Alpha Wave, and KKR, market expectations are high. Yet, historical patterns remind investors to weigh valuation metrics against growth execution before entry.
Valuation & Investment View
- Short-term: Expect volatility post listing amid oversubscription and profit-booking.
- Medium-term: Watch for growth in international revenue and margins.
- Long-term: Positive bias — strong brand positioning and omni-channel scalability.
Track listing-day sentiment using BankNifty Options to gauge near-term momentum shifts.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, notes that while brand-led IPOs attract retail enthusiasm, only consistent profit growth can sustain valuations. Lenskart’s listing will test whether consumer-tech brands can deliver long-term shareholder value in India’s evolving IPO landscape. Read more curated market insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Shark Tank IPOs
- Why Did Mamaearth Shares Underperform Post Listing?
- Is Emcure Pharma Fairly Valued After a Year of Flat Returns?
- Can Lenskart’s IPO Deliver Positive Returns Unlike Previous Shark Tank Listings?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
